Esperion Therapeutics Inc. (NASDAQ:ESPR)’s traded shares stood at 3.71 million during the last session, with the company’s beta value hitting 0.89. At the close of trading, the stock’s price was $1.84, to imply a decrease of -3.66% or -$0.07 in intraday trading. The ESPR share’s 52-week high remains $3.40, putting it -84.78% down since that peak but still an impressive 61.96% since price per share fell to its 52-week low of $0.70. The company has a valuation of $313.57M, with an average of 6.75 million shares over the past 3 months.
Esperion Therapeutics Inc. (NASDAQ:ESPR) trade information
After registering a -3.66% downside in the last session, Esperion Therapeutics Inc. (ESPR) has traded red over the past five days. The stock hit a weekly high of 2.5400, dropping -3.66% in its intraday price action. The 5-day price performance for the stock is -26.98%, and -10.24% over 30 days. With these gigs, the year-to-date price performance is -38.46%.
Esperion Therapeutics Inc. (ESPR) estimates and forecasts
Looking at statistics comparing Esperion Therapeutics Inc. share performance against respective industry, we note that the company has outperformed competitors. Esperion Therapeutics Inc. (ESPR) shares are 120.10% up over the last 6 months, with its year-to-date growth rate higher than industry average at 60.59% against 9.70%. Revenue is forecast to grow 106.30% this quarter before jumping 54.30% for the next one. The rating firms project that company’s revenue will grow 127.90% compared to the previous financial year.
Revenue forecast for the current quarter as set by 8 analysts is $84.51 million. Meanwhile, for the quarter ending Jun 2024, a total of 8 analyst(s) estimate revenue growth to $42.53 million.Earnings reports from the last fiscal year show that sales brought in $24.33 million and $25.79 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 247.40% before jumping 64.90% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 23.09% for the past 5-year period. While 2024 is set for a 80.92% return in earnings, projections for the next 5 years are at 16.90% annually.
ESPR Dividends
Esperion Therapeutics Inc. has its next earnings report out in May. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Esperion Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
